ArticleCase reports in dermatology
Dupilumab for Chronic Spontaneous Urticaria with Comorbid Type 2 Inflammatory Conditions: Case Report and Systematic Review of the Literature.
Article in Case reports in dermatology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Chronic spontaneous urticaria (CSU) is a heterogeneous, Th2-driven condition where standard therapies, including antihistamines and omalizumab, are often insufficient. Dupilumab, an IL-4Rα antagonist approved for several Th2-mediated diseases, has shown efficacy in CSU. We present a rare case of CSU coexisting with both asthma and eosinophilic gastroenteritis, successfully treated with dupilumab, highlighting the potential effectiveness and appropriateness of dupilumab in patients with multiple, simultaneous Th2-mediated comorbidities, and provide a systematic review of the literature. Case Presentation: A 32-year-old man with refractory CSU, asthma, and eosinophilic gastroenteritis was treated with dupilumab. The patient achieved complete remission of CSU, asthma, and eosinophilic gastroenteritis with dupilumab, with no reported side effects. A systematic literature search of PubMed and Embase identified eight studies comprising 25 CSU patients, most with coexisting atopic dermatitis or asthma. The majority achieved symptom control of urticaria as well as of the coexisting Th2 diseases, with only one report of mild side effects. Conclusions: Dupilumab is a suitable therapeutic option in patients with CSU and coexisting Th2-mediated conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.